Tuesday, September 22, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialsorforgliproneli lillystress urinary incontinenceobesity

Lilly opens Phase 3 orforglipron trial in women with stress urinary incontinence

The GZPS master protocol supports two independent studies comparing the once-daily oral GLP-1 tablet against placebo in women with obesity or overweight.

PR
By Priya Raman · Science Reporter
Sep 22 08:00 ETSource: ClinicalTrials.gov

The wire

  1. 01Eli Lilly registered NCT07202884, a recruiting Phase 3 master protocol testing once-daily orforglipron tablets versus placebo in adult women with stress urinary incontinence and obesity or overweight, starting 30 September 2025.
  2. 02Extends oral incretin development into a non-metabolic indication that clinicians often manage surgically or with pelvic floor therapy.
  3. 03Participation runs about 58 weeks from screening to safety follow-up; no efficacy data exist yet and the two sub-studies, GZS1 and GZS2, read out separately.

From the source

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Urinary Incontinence,Stress.

Read at clinicaltrials.gov
Source URL https://clinicaltrials.gov/study/NCT07202884